Launched by a team of experienced life science industry researchers. Abbratech Inc is structured around addressing various problems in the antibody development paradigm; that facts that the current systems are too slow and do not always result in consistent, renewable, and precise antibodies. The technology and approach devised by Abbratechs - designated EPIVOLVEsm technology - provides a comprehensive custom recombinant antibody discovery and development services platform.
